DeltaMed and Advera Health Analytics Launch Evidex Signal Detection and Management Platform in China

DeltaMed to offer marketing and support for healthcare organizations in the People’s Republic of China

DeltaMed Co., Ltd., a leading specialized Contract Research Organization dedicated to providing professional services in the area of pharmacovigilance, medical monitoring and writing and Advera Health Analytics, Inc., a market leader in cloud based, software-as-a-service pharmacovigilance solutions, today announced an agreement that will enable DeltaMed to market and support Advera Health’s Evidex®, a next generation drug safety signal detection and management platform, in the People’s Republic of China.

With this agreement DeltaMed will formally launch the availability of Evidex’s signal detection and management platform to pharmaceutical, biotech, and regulatory organizations in China. DeltaMed’s clients will be able to leverage Evidex to manage safety signals, inquiries, and requests from detection through resolution, and elicit actionable intelligence from drug safety data.

Recommended AI News: LogicMonitor Named a Strong Performer in Artificial Intelligence for IT Operations

“We are excited by this partnership and the launch of Evidex in the People’s Republic of China. 2020 has been a pivotal time in the global adoption of Evidex as a market leading pharmacovigilance signal detection and management platform. Expanding access to the particularly important China market has been a priority for Advera for quite some time,” said Brian Overstreet, President and CEO of Advera Health. “We are especially enthusiastic by the reach and success of DeltaMed in pharmacovigilance services and we know that they are ideally suited to help us expand our marketing reach in China and increase the use of Evidex internationally.”

Recommended AI News: ICC Partners with GigaIO to Offer NovArray HPC Solution

“We are eager to meet the demands of our clients in China for a next generation signal detection and management software solution,” said Howe Li, Founder and CEO of DeltaMed. “After surveying the market, it became clear that the Evidex platform is the ideal pharmacovigilance solution to help our clients with the pharmacovigilance challenges and opportunities that lie ahead in the coming decades.”

Since launching Evidex, Advera Health has been creating a next generation pharmacovigilance platform to connect disparate drug safety data sources and provide a user experience that elicits actionable intelligence from those data. The Evidex platform links to internal ICSR databases, FAERS, VigiBase, EDC, EVDAS, and other data and provides for a validated, audit ready environment to track and manage safety issues that are found in those data.

Recommended AI News: Bombardier Launches New EBI Sense Digital Service